depression

PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 Teva Pharmaceuticals has announced new findings from its ongoing IMPACT-TD...

WASHINGTON, D.C., April 24, 2026 The U.S. Food and Drug Administration has announced a series of accelerated regulatory actions...

CAMBRIDGE, Mass., March 31, 2026 Enveric Biosciences has strengthened its position in the rapidly evolving neuropsychiatric drug development space...

NEW YORK, USA | March 24, 2026 Gilgamesh Pharma, a clinical-stage neuroscience company focused on next-generation neuropsychiatric therapeutics, has...

Los Angeles, California – November 3, 2025 NeuroSigma, Inc., a Los Angeles-based bioelectronics company, has announced a groundbreaking publication...